Gallbladder cancer is highly aggressive cancer and affects Hispanic minorities, native Alaskans and is the leading cancer amongst women from Chile. Molecular characterization of this cancer is limited and therapeutic advances are very few. EGFR, MEK and PI3‐Kinase pathway aberrations were reported in small retrospective studies. However, profiling of several components of the multiple signaling cascades would predict disease behavior better than single isolated pathways. We propose to interface the extensive clinical and pathology expertise from Clinica Alemana (CAS), Chile with the molecular biology and proteomics resources provided by Dr. Gordon Mills and colleagues at MDACC and provide the first molecular and proteomic characterization of gallbladder cancer. Dr. Ivan Roa from CAS has a repository of resected, frozen cancer tissue‐an invaluable resource for proteomic studies and genome sequencing; both institutions have a FFPE tissue archive.